Zwitterionic chitosan derivative, a new biocompatible pharmaceutical excipient, prevents endotoxin-mediated cytokine release

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Bajaj, Gaurav ^a   Van Alstine, William G ^b   Yeo, Yoon ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOLYTE; BIOMATERIAL; CHITOSAN; ENDOTOXIN; EXCIPIENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BIOCOMPATIBILITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLOGY; HISTOLOGY; INFLAMMATION; MACROPHAGE FUNCTION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PH; SOLUBILITY; ANIMAL; CELL CULTURE; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; EVALUATION; INSTITUTE FOR CANCER RESEARCH MOUSE; MATERIALS TESTING; METABOLISM; PHYSIOLOGY;

MUS;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL PROLIFERATION; CELLS, CULTURED; CHITOSAN; CYTOKINES; DOWN-REGULATION; ENDOTOXINS; EXCIPIENTS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MATERIALS TESTING; MICE; MICE, INBRED ICR;

EID: 84856149567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030899     Document Type: Article

References (54)

1. Illum L, (1998) Chitosan and its use as a pharmaceutical excipient. Pharm Res 15: 1326-1331.
2. Baldrick P, (2009) The Safety of Chitosan as a Pharmaceutical Excipient. Regul Toxicol Pharmacol.
3. Qin C, Gao J, Wang L, Zeng L, Liu Y, (2006) Safety evaluation of short-term exposure to chitooligomers from enzymic preparation. Food Chem Toxicol 44: 855-861.
4. Hirano S, (1994) SOME ECOLOGICALLY-FRIENDLY APPLICATIONS OF CHITIN AND CHITOSAN IN BIOTECHNOLOGY. Abstracts of Papers of the American Chemical Society 207: 118-BTEC.
5. Hirano S, (1996) Chitin biotechnology applications. Biotechnol Annu Rev 2: 237-258.
6. Obara K, Ishihara M, Ishizuka T, Fujita M, Ozeki Y, et al. (2003) Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healing-impaired db/db mice. Biomaterials 24: 3437-3444.
7. Ishihara M, Nakanishi K, Ono K, Sato M, Kikuchi M, et al. (2002) Photocrosslinkable chitosan as a dressing for wound occlusion and accelerator in healing process. Biomaterials 23: 833-840.
8. Ono K, Ishihara M, Ozeki Y, Deguchi H, Sato M, et al. (2001) Experimental evaluation of photocrosslinkable chitosan as a biologic adhesive with surgical applications. Surgery 130: 844-850.
9. Ryu JH, Lee Y, Kong WH, Kim TG, Park TG, et al. (2011) Catechol-Functionalized Chitosan/Pluronic Hydrogels for Tissue Adhesives and Hemostatic Materials. Biomacromolecules 12: 2653-2659.
10. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y, (2000) Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharmaceutical development and technology 5: 77-85.
11. Bowman K, Leong KW, (2006) Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 1: 117-128.
12. Roy K, Mao H-Q, Huang S-K, Leong KW, (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nature Med 5: 387-391.
13. van der Merwe SM, Verhoef JC, Verheijden JHM, Kotzé AF, Junginger HE, (2004) Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. European journal of pharmaceutics and biopharmaceutics 58: 225-235.
14. VandeVord PJ, Matthew HWT, DeSilva SP, Mayton L, Wu B, et al. (2002) Evaluation of the biocompatibility of a chitosan scaffold in mice. Journal of Biomedical Materials Research 59: 585-590.
15. Nettles DL, Elder SH, Gilbert JA, (2002) Potential use of chitosan as a cell scaffold material for cartilage tissue engineering. Tissue Engineering 8: 1009-1016.
16. Muzzarelli RA, (2010) Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs 8: 292-312.
17. Ono K, Saito Y, Yura H, Ishikawa K, Kurita A, et al. (2000) Photocrosslinkable chitosan as a biological adhesive. J Biomed Mater Res 49: 289-295.
18. Amsden BG, Sukarto A, Knight DK, Shapka SN, (2007) Methacrylated Glycol Chitosan as a Photopolymerizable Biomaterial. Biomacromolecules 8: 3758-3766.
19. Park JH, Kwon S, Nam J-O, Park R-W, Chung H, et al. (2004) Self-assembled nanoparticles based on glycol chitosan bearing 5[beta]-cholanic acid for RGD peptide delivery. J Control Release 95: 579-588.
20. Park K, Kim J-H, Nam YS, Lee S, Nam HY, et al. (2007) Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release 122: 305-314.
21. Min KH, Park K, Kim Y-S, Bae SM, Lee S, et al. (2008) Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 127: 208-218.
22. Xu P, Bajaj G, Shugg T, Van Alstine WG, Yeo Y, (2010) Zwitterionic Chitosan Derivatives for pH-Sensitive Stealth Coating. Biomacromolecules.
23. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE, (2008) Preclinical Studies To Understand Nanoparticle Interaction with the Immune System and Its Potential Effects on Nanoparticle Biodistribution. Molecular Pharmaceutics 5: 487-495.
24. Mathews S, Kaladhar K, Sharma CP, (2006) Cell mimetic monolayer supported chitosan-haemocompatibility studies. J Biomed Mater Res A 79: 147-152.
25. Sagnella S, Mai-Ngam K, (2005) Chitosan based surfactant polymers designed to improve blood compatibility on biomaterials. Colloids Surf B Biointerfaces 42: 147-155.
26. Minami S, Suzuki H, Okamoto Y, Fujinaga T, Shigemasa Y, (1998) Chitin and chitosan activate complement via the alternative pathway. Carbohydrate Polymers 36: 151-155.
27. Yeo Y, Burdick JA, Highley CB, Marini R, Langer R, et al. (2006) Peritoneal application of chitosan and UV-cross-linkable chitosan. Journal of Biomedical Materials Research Part A 78A: 668-675.
28. Peluso G, Petillo O, Ranieri M, Santin M, Ambrosio L, et al. (1994) Chitosan-mediated stimulation of macrophage function. Biomaterials 15: 1215-1220.
29. Nishimura K, Ishihara C, Ukei S, Tokura S, Azuma I, (1986) Stimulation of cytokine production in mice using deacetylated chitin. Vaccine 4: 151-156.
30. Mori T, Irie Y, Nishimura SI, Tokura S, Matsuura M, et al. (1998) Endothelial cell responses to chitin and its derivatives. J Biomed Mater Res 43: 469-472.
31. Mori T, Okumura M, Matsuura M, Ueno K, Tokura S, et al. (1997) Effects of chitin and its derivatives on the proliferation and cytokine production of fibroblasts in vitro. Biomaterials 18: 947-951.
32. Canali MM, Porporatto C, Aoki MP, Bianco ID, Correa SG, (2010) Signals elicited at the intestinal epithelium upon chitosan feeding contribute to immunomodulatory activity and biocompatibility of the polysaccharide. Vaccine 28: 5718-5724.
33. Tanaka Y, Tanioka S, Tanaka M, Tanigawa T, Kitamura Y, et al. (1997) Effects of chitin and chitosan particles on BALB/c mice by oral and parenteral administration. Biomaterials 18: 591-595.
34. Chellat F, Grandjean-Laquerriere A, Le Naour R, Fernandes J, Yahia L, et al. (2005) Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials 26: 961-970.
35. Risbud M, Bhonde M, Bhonde R, (2001) Chitosan-polyvinyl pyrrolidone hydrogel does not activate macrophages: potentials for transplantation applications. Cell Transplant 10: 195-202.
36. Risbud MV, Bhonde MR, Bhonde RR, (2001) Effect of chitosan-polyvinyl pyrrolidone hydrogel on proliferation and cytokine expression of endothelial cells: implications in islet immunoisolation. J Biomed Mater Res 57: 300-305.
37. Kim M-S, Sung M-J, Seo S-B, Yoo S-J, Lim W-K, et al. (2002) Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid [beta] peptide and interleukin-1[beta]. Neuroscience Letters 321: 105-109.
38. Liu HT, Li WM, Li XY, Xu QS, Liu QS, et al. (2009) Chitosan oligosaccharides inhibit the expression of interleukin-6 in lipopolysaccharide-induced human umbilical vein endothelial cells through p38 and ERK1/2 protein kinases. Basic Clin Pharmacol Toxicol 106: 362-371.
39. Chen CL, Wang YM, Liu CF, Wang JY, (2008) The effect of water-soluble chitosan on macrophage activation and the attenuation of mite allergen-induced airway inflammation. Biomaterials 29: 2173-2182.
40. Nam KS, Kim MK, Shon YH, (2007) Inhibition of proinflammatory cytokine-induced invasiveness of HT-29 cells by chitosan oligosaccharide. J Microbiol Biotechnol 17: 2042-2045.
41. Yoon HJ, Moon ME, Park HS, Im SY, Kim YH, (2007) Chitosan oligosaccharide (COS) inhibits LPS-induced inflammatory effects in RAW 264.7 macrophage cells. Biochem Biophys Res Commun 358: 954-959.
42. Azab AK, Doviner V, Orkin B, Kleinstem J, Srebnik M, et al. (2007) Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat. Journal of Biomedical Materials Research Part A 83A: 414-422.
43. Raghoebar M, van den Berg WB, Huisman JAM, van Ginneken CAM, (1987) The cellular association of sodium salicylate and indomethacin in peritoneal fluid of ascites bearing mice. Inflammation Research 22: 314-323.
44. Kohane DS, Tse JY, Yeo Y, Padera R, Shubina M, et al. (2006) Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. Journal of Biomedical Materials Research Part A 77A: 351-361.
45. Guha M, Mackman N, (2001) LPS induction of gene expression in human monocytes. Cell Signal 13: 85-94.
46. Sagnella S, Mai-Ngam K, (2005) Chitosan based surfactant polymers designed to improve blood compatibility on biomaterials. Colloids and Surfaces B: Biointerfaces 42: 147-155.
47. Dufrane D, Steenberghe Mv, Goebbels R-M, Saliez A, Guiot Y, et al. (2006) The influence of implantation site on the biocompatibility and survival of alginate encapsulated pig islets in rats. Biomaterials 27: 3201-3208.
48. Hall JC, Heel KA, Papadimitriou JM, Platell C, (1998) The pathobiology of peritonitis. Gastroenterology 114: 185-196.
49. Anderson JM, Rodriguez A, Chang DT, (2008) Foreign body reaction to biomaterials. Semin Immunol 20: 86-100.
50. Usami Y, Okamoto Y, Minami S, Matsuhashi A, Kumazawa NH, et al. (1994) Migration of canine neutrophils to chitin and chitosan. J Vet Med Sci 56: 1215-1216.
51. Lee J, Cacalano G, Camerato T, Toy K, Moore MW, et al. (1995) Chemokine binding and activities mediated by the mouse IL-8 receptor. Journal of Immunology 155: 2158-2164.
52. Chellat F, Tabrizian M, Dumitriu S, Chornet E, Magny P, et al. (2000) In vitro and in vivo biocompatibility of chitosan-xanthan polyionic complex. Journal of Biomedical Materials Research 51: 107-116.
53. Wiegand C, Winter D, Hipler UC, (2010) Molecular-weight-dependent toxic effects of chitosans on the human keratinocyte cell line HaCaT. Skin Pharmacol Physiol 23: 164-170.
54. (2010) The United States Pharmacopeia: The National Formulary (USP33/NF28). Rockville, MD The United States Pharmacopeial Convention, Inc.